Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index.

Aoki C, Suzuki K, Kuroda H, Sagara M, Shimizu M, Kasai K, Aso Y.

Nagoya J Med Sci. 2017 Feb;79(1):9-16. doi: 10.18999/nagjms.79.1.9.

2.

Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial.

Matsushima Y, Takeshita Y, Kita Y, Otoda T, Kato K, Toyama-Wakakuri H, Akahori H, Shimizu A, Hamaguchi E, Nishimura Y, Kanamori T, Kaneko S, Takamura T.

BMJ Open Diabetes Res Care. 2016 Apr 19;4(1):e000190. doi: 10.1136/bmjdrc-2015-000190. eCollection 2016.

3.

Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes.

Fisman EZ, Tenenbaum A.

Cardiovasc Diabetol. 2015 Sep 29;14:129. doi: 10.1186/s12933-015-0294-0. Review.

4.

Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor.

Goldsmith F, Keenan MJ, Raggio AM, Ye X, Hao Z, Durham H, Geaghan J, Jia W, Martin RJ, Ye J.

PLoS One. 2015 May 4;10(5):e0126177. doi: 10.1371/journal.pone.0126177. eCollection 2015.

5.

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.

Gu N, Park MK, Kim TE, Bahng MY, Lim KS, Cho SH, Yoon SH, Cho JY, Jang IJ, Yu KS.

Drug Des Devel Ther. 2014 Oct 6;8:1709-21. doi: 10.2147/DDDT.S65678. eCollection 2014.

6.

Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin.

Chung HS, Suh S, Kim MY, Kim SK, Kim HK, Lee JI, Hur KY, Kim JH, Min YK, Lee MS, Kim KW, Kim SW, Chung JH, Lee MK.

J Diabetes Investig. 2014 Feb 12;5(1):51-9. doi: 10.1111/jdi.12127. Epub 2013 Sep 2.

7.

GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

Brunton S.

Int J Clin Pract. 2014 May;68(5):557-67. doi: 10.1111/ijcp.12361. Epub 2014 Feb 6. Review.

8.

Alogliptin.

Cada DJ, Levien TL, Baker DE.

Hosp Pharm. 2013 Jul;48(7):580-92. doi: 10.1310/hpj4807-580.

9.

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria.

Haluzík M, Frolík J, Rychlík I.

Int J Endocrinol. 2013;2013:895102. doi: 10.1155/2013/895102. Epub 2013 Sep 5. Review.

10.

Early Effect of Single-dose Sitagliptin Administration on Gastric Emptying: Crossover Study Using the (13)C Breath Test.

Nonaka T, Sekino Y, Iida H, Yamada E, Ohkubo H, Sakai E, Higurashi T, Hosono K, Endo H, Koide T, Takahashi H, Fujita K, Yoneda M, Goto A, Kusakabe A, Kobayashi N, Gotoh E, Maeda S, Nakajima A, Nosaka C, Inamori M.

J Neurogastroenterol Motil. 2013 Apr;19(2):227-32. doi: 10.5056/jnm.2013.19.2.227. Epub 2013 Apr 16.

11.

A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice.

Evans M, McEwan P, O'Shea R, George L.

Diabetes Ther. 2013 Jun;4(1):27-40. doi: 10.1007/s13300-012-0015-6. Epub 2012 Dec 8.

12.

β-cell preservation and regeneration for diabetes treatment: where are we now?

Karadimos MJ, Kapoor A, El Khattabi I, Sharma A.

Diabetes Manag (Lond). 2012 May 1;2(3):213-222.

13.

Loss of CD26 protease activity in recipient mice during hematopoietic stem cell transplantation results in improved transplant efficiency.

Yoo E, Paganessi LA, Alikhan WA, Paganessi EA, Hughes F, Fung HC, Rich E, Seong CM, Christopherson KW 2nd.

Transfusion. 2013 Apr;53(4):878-87. doi: 10.1111/j.1537-2995.2012.03826.x. Epub 2012 Aug 6.

14.
15.

Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus.

Chung HS, Lee MK.

Diabetes Metab J. 2011 Aug;35(4):411-7. doi: 10.4093/dmj.2011.35.4.411. Epub 2011 Aug 31.

16.

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.

Schweizer A, Dejager S, Foley JE, Kothny W.

Vasc Health Risk Manag. 2011;7:49-57. doi: 10.2147/VHRM.S16925. Epub 2011 Feb 4.

Supplemental Content

Support Center